Healthpoint, Ltd. -- Inside Healthpoint

The following studies require adobe reader to view/print. Get adobe reader here

Combining Wound Debridement Modalities with Negative Pressure Wound Therapy

Combining Wound Care Modalities

Efficacy of Chemical enzymes in Wound Debridment

Papain, Urea, Chlorophyllin Copper Complex Sodium Ointment and Balsam Peru, Castor Oil USP/NF, Trypsin USP Ointment in the Treatment and Healing of Recurrent Stage II and Stage III Pressure Ulcers

Use of a Papain, Urea Enzymatic Debriding Ointment on a Pediatric Patient with an IV Infiltrate Burn

Papain, Urea, Chrlorophyllin Copper Complex Sodium Active Components Tested Single-Variably in Acute Infected Pig Wounds

Efficiency and Convenience of Spray

Managing Urinary Incontinence & Catheters: Revised Regulations Associated with F315 CME

Presented by Dr. Mikel Gray, professor and nurse practitioner from the Department of Urology and the School of Nursing at the University of Virginia, this webcast reviews the revised F315 regulations relating to urinary incontinence and catheters. Topics covered include the historical and administrative process that led to the F315 revision and a discussion of the essential elements for the assessment and management of urinary incontinence in the long-term care setting. Finally, Dr Gray examines the indications for inserting an indwelling catheter and its management.
1.0 CE/CME

Mapping Wound & Skin Care Decisions to Assessment and Documentation Details: Focus on Quality Care

This webcast describes the importance of a complete and well-rounded wound and skin care formulary as the first line of defense for cost effective outcomes and quality care. Participants will learn how best to map the proper assessment and documentation skills to the federal regulations that currently govern long term care facilities. Also included is a discussion of the importance of incorporating accurate assessment, documentation, and intervention processes based on relevant guidelines.
2.0 CE/CME

Click here to register at TheWoundInstitute.com to view these archived webcasts

The following studies require adobe reader to view/print. Get adobe reader here

ACCUZYME ® Ointment
Debridement
Infection
OASIS® Wound Matrix
PRUDOXIN® Cream
XENADERM® Ointment

The following videos require Flash Player to view. Get Flash Player here

OASIS® Case Study
OASIS® Application Technique
OASIS® Mode of Action
PANAFIL® Case Study 1
PANAFIL® Case Study 2
PANAFIL® Case Study 3

Prevention and Early Intervention of Pressure Ulcers CE:1.0*
Physiological Foundation of Wound Assessment CE:1.8*
A Prescription for Effective Wound Management CE:1.0*
Diabetic Foot Ulcers CE:1.0* Venous Ulcers CE:1.0*

*Healthpoint is a Provider approved by the California Board of Registered Nursing, Provider No.CEP 12484. Accreditaiton refers to recognition of continuing nursing education activities only and does not imply Commission on Accreditation approval or endorsement of any commerical product.

For more information about these programs, contact your Healthpoint representative, or call 1-800-441-8227.

HEALTHPOINT MISSION
Healthpoint is uniquely committed to the development and marketing of innovative, quality products for the prevention and treatment of diseased and traumatized skin and related soft tissue.

HERITAGE
Healthpoint was established at the end of 1992. However, our heritage spans more than sixty years beginning in 1938, in San Antonio, Texas, as Texas Pharmacal Company (TPC). TPC specialized in the development of new skin care technologies and marketed its products in an emerging medical specialty called Dermatology. Many first-of-a-kind products came out of TPC including the first sunscreen, hypoallergenic product line, and benzoyl peroxide acne product, as well as several popular consumer brands like Cetaphil® and Lubriderm®.

TPC grew steadily and was ultimately sold in 1966 to the Warner Lambert Company. Warner-Lambert used the San Antonio facility to manufacture Lubriderm and other products. In 1979, Alcon Laboratories, a subsidiary of Nestlé, acquired TPC from Warner-Lambert. In 1988, the facility became off-strategy for Alcon, and Alcon announced its intention to sell or close the San Antonio site.

Recognizing its inherent value from technical and manufacturing standpoints, DFB Pharmaceuticals (Healthpoint’s parent company) purchased the San Antonio facility in late 1990. The strategy behind the purchase was to provide contract-manufacturing services and to leverage the organization’s technical capabilities to develop and market unique products to the healthcare industry.

In 1992, DFB created Healthpoint to market such technologies. Products initially included wound care, incontinent care, and skin care lines sold to hospitals and long-term care facilities. This flagship division became known as Tissue Management. Today, Healthpoint Tissue Management is considered an innovative leader in the advanced wound care marketplace. In 1996, Healthpoint acquired a line of products from Galderma providing critical mass to enter the dermatology market. Today, Healthpoint Dermatology enjoys a rich pharmaceutical pipeline that positions it for substantial growth. In 2002, Healthpoint formed a Surgical division to launch a platform of products based on a patented antiseptic technology.

With our rich heritage, strong business performance, and a keen eye on the future, Healthpoint remains uniquely committed to the development and marketing of innovative, quality products for the prevention and treatment of diseased and traumatized skin and related soft tissue.